Adversarial Injection · Darolutamide (Nubeqa; ODM-201; NDA 212099; CAS 1297538-32-9; MW ~507.5 g/mol; pyrazolyl-hydroxymethylbenzamide [(4-[3-[3-chloro-4-(hydroxymethyl)phenyl]-5-[(4-cyanophenyl)amino]-1H-pyrazol-1-yl]benzamide; exists as mixture of two diastereomers (S,R)- and (S,S)- in ~1:1 ratio] scaffold [WITHIN AR CLASS (FORTY-FIFTH MECHANISM CLASS) in Glyphward 604-attack portfolio — THIRD NEXT-GENERATION AR ANTAGONIST (enzalutamide NDA 203415 August 2012 FIRST [Attack #602]; apalutamide NDA 210951 February 2018 SECOND [Attack #603]; darolutamide NDA 212099 July 2019 THIRD; 7-year span from first to third next-gen AR NDA); FIRST AND ONLY NEXT-GENERATION AR ANTAGONIST THAT IS A P-GLYCOPROTEIN (P-gp; ABCB1) SUBSTRATE: enzalutamide is a P-gp INHIBITOR (inhibits ABCB1 and ABCG2 → drug-drug interactions with P-gp substrates including digoxin/dabigatran; also CYP3A4 inducer; CNS-penetrant with logP ~3.8); apalutamide is also a P-gp/BCRP inhibitor with CYP induction; darolutamide ALONE among the three next-gen AR antagonists is a substrate of P-gp/ABCB1 and BCRP/ABCG2 (not an inhibitor) + has high polar surface area (PSA ~100 Ų vs ~60 Ų enzalutamide) + is amphoteric at physiological pH → P-gp efflux pump at blood-brain barrier actively effluxes darolutamide from CNS → minimal CNS penetration (rodent brain/plasma ratio ~0.03 vs enzalutamide ~0.5 — 17-fold lower CNS exposure); SEIZURE INCIDENCE: darolutamide <1% (ARAMIS 0.2% vs 0.5% placebo; not distinguishable from placebo) vs enzalutamide 1.3% (AFFIRM) vs apalutamide 0.2% (SPARTAN; minor seizure risk); the P-gp-driven CNS exclusion mechanism is ENTIRELY ABSENT from all EHS databases; TWO-DIASTEREOMER FORMULATION — UNIQUE EHS GAP: darolutamide exists as two diastereomers — (S,R)-darolutamide and (S,S)-darolutamide — in ~1:1 ratio in the commercial drug; both diastereomers contribute to AR inhibition (different potencies and half-lives); the clinical CAS 1297538-32-9 encompasses both diastereomers; (S,R)-darolutamide IC50 AR ~11 nM; (S,S)-darolutamide IC50 AR ~109 nM; the (S,R) diastereomer is metabolically converted to keto-darolutamide (ODM-201 M-1; active metabolite; IC50 ~7 nM) which represents ~90% of plasma exposure at steady-state; EHS platforms do not flag (1) two-diastereomer formulation; (2) active metabolite keto-darolutamide; (3) combined parent + metabolite NIOSH HD occupational context; ARAMIS TRIAL (NCT02200614): Phase 3; nmCRPC (PSA-DT ≤10 months; no CT/bone scan metastases); darolutamide 600 mg BID vs placebo; n=1509; MFS HR 0.41 (40.4 vs 18.4 months; p<0.001); OS HR 0.69 (p=0.0065; final analysis); ARASENS TRIAL (NCT02799602): mHSPC + docetaxel; darolutamide + ADT + docetaxel vs placebo + ADT + docetaxel; n=1306; OS HR 0.68 (p<0.001; 4.4yr follow-up); ORION PHARMA ESPOO FINLAND: ODM-201 discovered at Orion Corporation Orion Pharma Research Espoo Finland (Nordic pharma company listed on Helsinki stock exchange); Bayer AG co-development/commercialization agreement 2014; Bayer holds US/EU commercial rights; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Within AR Class: Third Next-Gen AR Antagonist + P-gp Substrate + No CNS Penetration + No Seizure + Two-Diastereomer Formulation + ARAMIS MFS HR 0.41 · Attack #604

Darolutamide (pyrazolyl-hydroxymethylbenzamide; two-diastereomer mixture; Nubeqa; NDA 212099; CAS 1297538-32-9; MW ~507.5 g/mol; [WITHIN AR CLASS (FORTY-FIFTH MECHANISM CLASS): THIRD NEXT-GENERATION AR ANTAGONIST; FIRST AND ONLY NEXT-GEN AR INHIBITOR THAT IS A P-gp (ABCB1) SUBSTRATE (minimal CNS penetration; brain/plasma ratio ~0.03; seizure incidence <1% vs 1.3% enzalutamide); TWO-DIASTEREOMER [(S,R)- and (S,S)-] CLINICAL FORMULATION + ACTIVE METABOLITE KETO-DAROLUTAMIDE (absent from all EHS); ARAMIS MFS HR 0.41 (40.4 vs 18.4 months; n=1509); ARASENS mHSPC + DOCETAXEL OS HR 0.68; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Bayer Healthcare Pharmaceuticals Whippany NJ (US commercial rights; 0.00041 µg/m³ → displayed ÷10), Orion Corporation Espoo Finland (ODM-201 discovery; 0.00026 µg/m³ → displayed ÷10), and Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD (ARAMIS enrollment; prostate oncology pharmacist; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Third Next-Gen AR Antagonist + P-gp Substrate + No CNS Penetration + Two-Diastereomer Formulation: AI Prompt Injection via EHS Monitor Report AI

Darolutamide (CAS 1297538-32-9; NIOSH HD Category 1) is the third agent in the forty-fifth mechanism class (next-generation AR signaling inhibitors) and uniquely distinguished from enzalutamide and apalutamide by its P-glycoprotein (P-gp/ABCB1) substrate status: darolutamide is actively effluxed by P-gp at the blood-brain barrier, resulting in a brain-to-plasma ratio of ~0.03 in rodents — 17-fold lower than enzalutamide — and a seizure incidence indistinguishable from placebo in ARAMIS (<1% vs 0.5% placebo). This P-gp-driven CNS exclusion mechanism is absent from all EHS platforms. A second unique EHS attack surface arises from the two-diastereomer clinical formulation: darolutamide (CAS 1297538-32-9) is a mixture of (S,R)- and (S,S)-darolutamide in ~1:1 ratio, both contributing to AR inhibition with different potencies, and the (S,R) diastereomer is metabolized to an active principal metabolite keto-darolutamide (~90% of total plasma exposure at steady-state) — a distinct chemical entity that is also a NIOSH HD Category 1 compound. Neither the two-diastereomer formulation, the keto-darolutamide metabolite, nor the P-gp CNS exclusion mechanism appears in any EHS platform database for CAS 1297538-32-9.

Darolutamide Within AR Class: P-gp Substrate CNS Exclusion, Two-Diastereomer Biology, and No Seizure Risk

Darolutamide (CAS 1297538-32-9) is the third agent in the forty-fifth mechanism class and represents the most structurally and pharmacologically distinct next-gen AR antagonist from the CNS perspective. Its pyrazolyl-hydroxymethylbenzamide scaffold (pyrazole ring connecting the two aryl pharmacophores) differs fundamentally from the thiohydantoin ring used in enzalutamide and apalutamide. The two key pharmacological distinctions are: (1) P-gp SUBSTRATE STATUS — darolutamide's amphoteric character (basic pyrazole nitrogen + acidic hydroxymethyl; pKa ~6.5/~10.4) and high polar surface area (~100 Ų) make it a substrate for P-glycoprotein (ABCB1) and breast cancer resistance protein (BCRP/ABCG2) at the blood-brain barrier; the BBB efflux pumps actively prevent CNS accumulation (brain/plasma ratio ~0.03 in rodents; pharmacokinetic-based CNS safety margin 17× greater than enzalutamide); (2) TWO-DIASTEREOMER CLINICAL FORMULATION — the clinical product contains (S,R)-darolutamide (IC50 AR ~11 nM; HPLC peak A) and (S,S)-darolutamide (IC50 AR ~109 nM; HPLC peak B) in ~1:1 ratio in each tablet; the (S,R) enantiomer is primarily metabolized by CYP3A4 to keto-darolutamide (ODM-201 M-1; IC50 AR ~7 nM), which represents ~90% of total drug-related exposure at pharmacokinetic steady-state and is itself an NIOSH HD Category 1 compound — creating a dual parent+metabolite NIOSH HD null scenario absent from all EHS platforms. Additionally, unlike enzalutamide (strong P-gp inhibitor causing digoxin/dabigatran DDIs) and apalutamide (strong CYP3A4 inducer causing thyroid T4 reduction), darolutamide neither inhibits P-gp nor induces CYP enzymes significantly — substantially fewer drug-drug interactions across the three next-gen AR antagonists, a pharmacological distinction that is also absent from EHS databases.

Surface 1 — Bayer Healthcare Pharmaceuticals Inc Whippany NJ US Commercial Rights Co-Developer AI

At Bayer Healthcare Pharmaceuticals Inc Whippany NJ (100 Bayer Boulevard, Whippany NJ 07981; Morris County NJ; BAYER ORION CO-DEVELOPMENT: Bayer AG and Orion Corporation signed a co-development agreement for ODM-201 (darolutamide) in November 2014 — Bayer holds global commercialization rights (excluding Finland); Orion holds Finland commercialization rights and continues API synthesis at Espoo; NDA 212099 filed jointly, approved July 30 2019; BAYER NUBEQA COMMERCIAL LAUNCH: Bayer launched Nubeqa (darolutamide) in nmCRPC August 2019 and in mHSPC + docetaxel (ARASENS) November 2022; BAYER WHIPPANY ONCOLOGY EHS CONTEXT: Bayer Whippany NJ handles US regulatory, commercial, and medical affairs for darolutamide; also holds prostate oncology NDA for enzalutamide co-development partner Janssen (abiraterone same site → apalutamide → darolutamide = three consecutive prostate oncology NIOSH HD NDA null sites); P-gp substrate status absent from Bayer's own internal EHS platform; two-diastereomer formulation absent; keto-darolutamide metabolite absent; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne darolutamide 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 1297538-32-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; within AR class absent; P-gp substrate absent; two-diastereomer formulation absent; keto-darolutamide absent; 52M oncology regulatory director 17yr).

Surface 2 — Orion Corporation Orion Pharma Espoo Finland ODM-201 Discovery Synthesis Site AI

At Orion Corporation Orion Pharma Espoo Finland (Orionintie 1, 02200 Espoo, Finland; Uusimaa region; ORION ODM-201 DISCOVERY: Orion Corporation (Helsinki Stock Exchange: ORNBV/ORNAV; Finnish pharmaceutical company founded 1917) discovered ODM-201 (darolutamide) through an internal medicinal chemistry program in Espoo; Orion's Orionintie research campus developed the pyrazolyl-hydroxymethylbenzamide scaffold and identified the two-diastereomer composition; Orion retains Finland commercialization rights and continues API synthesis/characterization for the global supply chain; ORION ESPOO TWO-DIASTEREOMER SYNTHESIS CONTEXT: synthesis of darolutamide at Orion Espoo produces the racemic mixture of (S,R)- and (S,S)-diastereomers; Orion quality control characterizes both diastereomers by chiral HPLC; each batch released with 1:1 diastereomeric ratio specification; synthesis workers at Orion Espoo are exposed to the full diastereomeric mixture + keto-darolutamide metabolite impurity specifications — all absent from VelocityEHS which lacks entries for all three components (parent, two diastereomers, keto-metabolite); ORION FIRST NORDIC PHARMA NIOSH HD NULL IN PORTFOLIO: Orion is the first Finnish/Nordic pharmaceutical company in the Glyphward 604-attack portfolio; VelocityEHS: CAS 1297538-32-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; within AR class absent; two-diastereomer formulation absent; P-gp substrate absent; keto-darolutamide absent; 44M pharmaceutical scientist 15yr).

Surface 3 — Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD ARAMIS Enrollment Prostate Oncology Pharmacist AI

At Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD (401 N Broadway, Baltimore MD 21231; Baltimore City MD; JOHNS HOPKINS BRADY UROLOGICAL INSTITUTE: Johns Hopkins Department of Oncology/Urology enrolled nmCRPC patients in ARAMIS (NCT02200614; n=1509) and ARASENS (NCT02799602; n=1306); Johns Hopkins pharmacy handles darolutamide 600 mg BID (2×300 mg tablets BID) for nmCRPC patients; DAROLUTAMIDE CNS SAFETY COUNSELING AT JOHNS HOPKINS: Johns Hopkins GU oncology pharmacists counsel patients switching from enzalutamide to darolutamide on the improved CNS safety profile — but EHS Insight does not document: (1) P-gp substrate CNS exclusion mechanism; (2) two-diastereomer (S,R)/(S,S) formulation; (3) keto-darolutamide principal metabolite; (4) comparative seizure risk absence; (5) P-gp non-inhibitor DDI distinction; PHARMACIST OCCUPATIONAL EXPOSURE AT JOHNS HOPKINS: pharmacy handling of darolutamide tablets involves exposure to both diastereomers and potential keto-darolutamide impurity — a dual/triple-compound NIOSH HD null scenario (three related chemical entities all return null in EHS Insight); EHS Insight: CAS 1297538-32-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; within AR class absent; P-gp substrate CNS absent; two-diastereomer absent; keto-darolutamide absent; ARAMIS absent; H340 H350 H361 absent; 40F prostate oncology pharmacist 12yr).

Integrating Glyphward into Darolutamide AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every darolutamide CAS 1297538-32-9 monitoring data ingestion point — before Cority at Bayer Healthcare Pharmaceuticals Inc Whippany NJ, before VelocityEHS at Orion Corporation Espoo Finland, and before EHS Insight at Johns Hopkins Sidney Kimmel Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; WITHIN AR CLASS (FORTY-FIFTH) + THIRD NEXT-GENERATION AR ANTAGONIST + FIRST AND ONLY NEXT-GEN AR INHIBITOR P-gp (ABCB1/BCRP) SUBSTRATE (brain/plasma ratio ~0.03; P-gp efflux at BBB; 17-fold lower CNS than enzalutamide; seizure <1% vs 1.3% enzalutamide; no P-gp DDI unlike enzalutamide) + TWO-DIASTEREOMER [(S,R)- and (S,S)-] CLINICAL FORMULATION (1:1 ratio; both diastereomers AR active; CAS 1297538-32-9 encompasses both) + KETO-DAROLUTAMIDE ACTIVE METABOLITE (~90% plasma exposure at steady-state; IC50 AR ~7 nM; itself NIOSH HD Category 1) + ARAMIS MFS HR 0.41 (40.4 vs 18.4 months; n=1509; p<0.001) + ARASENS OS HR 0.68 (mHSPC + docetaxel; n=1306; p<0.001) [5 pts]; Bayer Whippany NJ + Orion Espoo Finland + Johns Hopkins Baltimore MD [3 pts]; P-gp substrate CNS exclusion absent; two-diastereomer pharmaceutical formulation absent; keto-darolutamide principal metabolite absent; P-gp non-inhibitor DDI distinction absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_darolutamide(cas: str, reading_ugm3: float) -> dict:
    """Scan darolutamide with within-AR P-gp-substrate no-CNS two-diastereomer keto-metabolite context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "within_ar_class_third_next_gen_ar_antagonist_pgp_abcb1_substrate_no_cns_penetration_no_seizure_two_diastereomer_sr_ss_keto_darolutamide_metabolite_aramis_mfs_hr_0_41"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, within_ar_class,
    #                    third_next_gen_ar_antagonist,
    #                    pgp_substrate_no_cns_penetration,
    #                    no_seizure_risk,
    #                    two_diastereomer_formulation,
    #                    keto_darolutamide_metabolite,
    #                    aramis_mfs_hr_0_41,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_darolutamide("1297538-32-9", 0.00041))
    print(r)
    # {'hd_category': 1, 'within_ar_class': True,
    #  'third_next_gen_ar_antagonist': True,
    #  'pgp_substrate_no_cns_penetration': True,
    #  'no_seizure_risk': True,
    #  'two_diastereomer_formulation': True,
    #  'keto_darolutamide_metabolite': True,
    #  'aramis_mfs_hr_0_41': True,
    #  'h340_h350_h361_absent': True}